Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx raises £500,000 to progess cancer trial

ValiRx has one drug, VAL201, going through phase I/II trials
ValiRx raises £500,000 to progess cancer trial
ValiRx has one drug, VAL201, going through phase I/II trials

ValiRx (LON:VAL) has raised £503,000 gross through a placing at 12p per to fund its drug development pipeline.

ValiRx has one drug, VAL201, going through  phase I/II trials, and has made an application to start a second for another cancer treatment, VAL401.

Satu Vainikka, chief executive said: "We are delighted to be able to raise additional funds through this equity placing in a challenging market.

“These funds will enable the company to progress the clinical trial activity that was recently announced."

PhilW.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Big Picture
May 19 2016

Related Articles

Cancer
March 31 2016
This broad coverage protects the company's lead immunotherapy, ImMucin
blood.jpg
September 10 2015
VolitionRx’s tests are based on the science of Nucleosomics, which identifies and measures nucleosomes in the bloodstream.
Lab_56a610b229ca5.jpg
January 25 2016
Broker N+1 Singer said: “The licensing agreement with a large US biotech is excellent news and illustrates the commercial potential of Abzena’s ThioBridge platform for the design of better antibody-drug conjugate drugs.”

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.